Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Zynex raises FY20 revenue view to $78M-$83M from $75M-$80M » 09:32
04/07/20
04/07
09:32
04/07/20
09:32
ZYXI

Zynex

$11.13 /

+1.23 (+12.42%)

Consensus is for FY20…

Consensus is for FY20 revenue $72.38M. The Company is increasing its FY20 revenue estimate to between $78M-$83M from $75M-$80M. The updated revenue estimate is now approximately 72%-83% above last year's full year revenue of $45.5M. FY20 estimated adjusted EBITDA remains unchanged at $15.0M-$18.0M. The company said: "Similar to many companies we have seen the impact of the COVID-19 pandemic, not only on the availability of physicians to prescribe our products but also on navigating employee and supply chain issues. March orders were down 15% compared to the average number of orders in January and February 2020, which is a smaller decline than we had expected considering the nationwide impact of COVID-19. The numbers have since stabilized and remain constant through the last 3 weeks of March and the early days of April." The company added, "Our cash collections in the Q1 of this year were strong which adds to our confidence in the full year estimates. We continue to add sales reps and train our sales force. In the month of March, we added 32 sales reps and we still expect to reach our goal of filling all 400 territories throughout the US by November of this year."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Zynex raises Q1 revenue view to $14.9M-$15.4M from $14.0M-$14.5M » 09:28
04/07/20
04/07
09:28
04/07/20
09:28
ZYXI

Zynex

$11.13 /

+1.23 (+12.42%)

Consensus is for Q1…

Consensus is for Q1 revenue $14.13M. Zynex reports Q1 orders were 126% above the number of orders in the Q1 of FY19 and 3% sequentially above the Q4 of FY9. In the Q4 of FY19, orders grew 129% year-over-year. Due to the solid increase in orders and strong collections the Company has updated its previous estimate for the first quarter of 2020 to between $14.9M-$15.4M compared to the previous estimate of between $14.0M-$14.5M. Q1 Adjusted EBITDA is now expected to come in between $2.8M-$3.3M up half a million from the previous estimate.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Initiation
Northland starts Zynex at Outperform on pain management potential » 07:58
04/01/20
04/01
07:58
04/01/20
07:58
ZYXI

Zynex

$11.05 /

+0.25 (+2.31%)

Northland analyst James…

Northland analyst James Terwilliger initiated coverage of Zynex with an Outperform rating and $15 price target. Zynex participates in the pain management and rehabilitation market, which the company estimates is approximately $500M worldwide, Terwilliger tells investors in a research note. The analyst believes the pain management market is experiencing significant disruption due to the safety and legal issues surrounding the opioid epidemic and that Zynex will be able to capture additional share.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Zynex initiated with an Outperform at Northland » 07:47
04/01/20
04/01
07:47
04/01/20
07:47
ZYXI

Zynex

$11.05 /

+0.25 (+2.31%)

Northland analyst James…

Northland analyst James Terwilliger initiated coverage of Zynex with an Outperform rating and $15 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
Zynex price target raised to $15 from $13 at H.C. Wainwright » 09:11
02/28/20
02/28
09:11
02/28/20
09:11
ZYXI

Zynex

$11.95 /

-0.66 (-5.23%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen raised the firm's price target on Zynex to $15 from $13 and reiterates a Buy rating on the shares. The company reported 2019 sales growth of 43% and its 2020 guidance suggests even stronger growth at around 70%, Chen tells investors in a post-earnings research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:12
02/27/20
02/27
19:12
02/27/20
19:12
SCOR

comScore

$3.00 /

-0.11 (-3.54%)

, FTCH

Farfetch

$9.54 /

-0.33 (-3.35%)

, ZYXI

Zynex

$11.95 /

-0.66 (-5.23%)

, SWN

Southwestern Energy

$1.30 /

-0.11 (-7.83%)

, ICAD

iCAD

$10.86 /

-0.46 (-4.06%)

, NPTN

NeoPhotonics

$6.19 /

-0.125 (-1.98%)

, AMC

AMC Entertainment

$6.08 /

+0.165 (+2.79%)

, TTD

Trade Desk

$250.42 /

-16.58 (-6.21%)

, NKTR

Nektar

$20.59 /

-0.81 (-3.79%)

, FTAI

Fortress Transportation

$18.07 /

-0.8 (-4.24%)

, WDAY

Workday

$171.15 /

-4.19 (-2.39%)

, LYV

Live Nation

$57.73 /

-3.05 (-5.02%)

, OPRX

OptimizeRx

$9.98 /

-1.32 (-11.68%)

, SGMO

Sangamo

$6.67 /

-0.22 (-3.19%)

, FTSV

Forty Seven

$48.78 /

+0.28 (+0.58%)

, BHVN

Biohaven Pharmaceutical

$40.99 /

-3.49 (-7.85%)

, GDI

Gardner Denver

$33.67 /

-2.12 (-5.92%)

, BIG

Big Lots

$22.44 /

-0.36 (-1.58%)

, GPOR

Gulfport Energy

$0.91 /

-0.0949 (-9.44%)

, BYND

Beyond Meat

$106.14 /

-6.31 (-5.61%)

, RUN

Sunrun

$20.32 /

-0.61 (-2.91%)

, CHRS

Coherus Biosciences

$19.18 /

-1.21 (-5.93%)

, GKOS

Glaukos

$61.32 /

-0.03 (-0.05%)

, AAOI

Applied Optoelectronics

$9.56 /

-0.62 (-6.09%)

, VMW

VMware

$135.79 /

-8.51 (-5.90%)

, EB

Eventbrite

$16.98 /

-0.74 (-4.18%)

, AAXN

Axon

$77.16 /

-3.3 (-4.10%)

, MYL

Mylan

$18.62 /

-0.94 (-4.81%)

, IQ

iQIYI

$24.44 /

+0.17 (+0.70%)

, SPPI

Spectrum

$2.41 /

-0.2 (-7.66%)

, DELL

Dell Technologies

$43.63 /

-2.31 (-5.03%)

, CARA

Cara Therapeutics

$15.36 /

-0.55 (-3.46%)

, ADSK

Autodesk

$180.36 /

-10.53 (-5.52%)

, RIGL

Rigel Pharmaceuticals

$2.05 /

-0.13 (-5.96%)

, PSTG

Pure Storage

$15.03 /

-0.835 (-5.26%)

, BBBY

Bed Bath & Beyond

$10.28 /

-0.32 (-3.02%)

UP AFTER EARNINGS:…

UP AFTER EARNINGS: comScore (SCOR) up 20.5%... Farfetch (FTCH) up 15.7%... Zynex (ZYXI) up 11.6%... Southwestern Energy (SWN) up 10.0%... iCAD (ICAD) up 10.0%... NeoPhotonics (NPTN) up 10.0%... AMC Entertainment (AMC) up 8.1%... Trade Desk (TTD) up 6.2%... Nektar Therapeutics (NKTR) up 5.9%...Fortress Transportation (FTAI) up 4.0%... Workday (WDAY) up 2.5%... Live Nation (LYV) up 2.2%... OptimizeRX (OPRX) up 2.1%. ALSO HIGHER: Sangamo (SGMO) up 39.5% after entering gene regulation therapy partnership with Biogen... Forty Seven (FTSV) up 29.1% after Bloomberg speculation about approach from Gilead... Biohaven (BHVN) up 6.0% after getting FDA approval for acute treatment of migraine... Garden Denver (GDI) up 2.1% after entering S&P500 index... DOWN AFTER EARNINGS: Big Lots (BIG) down 28.3%... Gulfport Energy (GPOR) down 11.1%... Beyond Meat (BYND) down 10.0%... Sunrun (RUN) down 10.0%... Coherus BioSciences (CHRS) down 8.8%... Glaukos (GKOS) down 7.5%... Applied Optoelectronics (AAOI) down 6.8%... VMWare (VMW) down 6.0%... Eventbrite (EB) down 5.4%... Axon Enterprise (AAXN) down 4.2%... Mylan (MYL) down 3.6%... iQIYI (IQ) down 3.4%... Spectrum Pharma (SPPI) down 3.3%... Dell Technologies (DELL) down 3.3%... Cara Therapeutics (CARA) down 3.2%... Autodesk (ADSK) down 2.6%... Rigel Pharma (RIGL) down 2.5%... Pure Storage (PSTG) down 2.1%. ALSO LOWER: Bed Bath Beyond (BBBY) down 2.0% after announcing strategic restructuring and job cuts. Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Zynex sees FY20 revenue $75M-$80M, consensus $63.5M  16:12
02/27/20
02/27
16:12
02/27/20
16:12
ZYXI

Zynex

$11.95 /

-0.66 (-5.23%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Zynex sees Q1 revenue $14.0M-$14.5M , consensus $13.14M  16:12
02/27/20
02/27
16:12
02/27/20
16:12
ZYXI

Zynex

$11.95 /

-0.66 (-5.23%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Zynex reports Q4 EPS 9c, consensus 8c » 16:11
02/27/20
02/27
16:11
02/27/20
16:11
ZYXI

Zynex

$11.90 /

-0.71 (-5.63%)

Reports Q4 revenue…

Reports Q4 revenue $14.2M, consensus $13.77M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Zynex receives FDA clearance for blood volume monitor » 09:13
02/25/20
02/25
09:13
02/25/20
09:13
ZYXI

Zynex

$13.41 /

+1.52 (+12.78%)

Zynex announced the U.S.…

Zynex announced the U.S. FDA granted 510(k) clearance for sale in the U.S. for the CM-1500 Blood Volume Monitor.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.